Advancing the Science

Mayo Clinic Medical Science Blog – an eclectic collection of research- and research education-related stories: feature stories, mini news bites, learning opportunities, profiles and more from Mayo Clinic.


Member has chosen to not make this information public.

Posts (47)

Tue, Sep 17 6:00am · Mayo Clinic Startup Earns World Economic Forum Award

With the promise of potential lifesaving treatments like chimeric
antigen receptor (CAR) T-Cell therapy
comes complex challenges. For instance:
how can we be sure the right cells are going to the right patient? How can we communicate
problems with manufacturing that would affect a patient’s treatment schedule?

To address those concerns, Mayo Clinic startup company Vineti developed first-of-its-kind software package
tracking for cell therapies. The software meticulously monitors quality control
during every step of the cell’s journey from extraction to infusion. Vineti’s groundbreaking
product captured a World Economic
Forum Technology Pioneer Award
in the field of health. Given to early stage
companies, this award recognizes new technologies and innovations poised for
significant impact on business and society.

Andrew Danielsen

“Creating new products is an additional way that Mayo Clinic
can improve patient care.  It’s a way to
amplify our staff’s talent in terms of meeting the needs of a large number of
patients. A single drug, one diagnostic test or one piece of software could positively
affect tens of millions of patients,” says Andrew Danielsen, chair of Mayo Clinic Ventures. “Having one of
Mayo Clinic’s startups win this award is a validation of our staff’s work to
bring a very innovative product to market.”

Vineti’s software reflects a new era of complex care delivered
at Mayo Clinic. Before CAR T-cell therapy, cell processing was typically done within
the treating institution. For CAR T, cells are shipped to an outside pharmaceutical
company where they are genetically modified with potential power to kill

Yi Lin, M.D., Ph.D.

“This adds a new layer of complexity to cell processing that
we have not had in the past,” says Yi
Lin, M.D., Ph.D.
, a hematologist who is the Chair of the Cell Therapy
Cross-Disciplinary Group at Mayo
Clinic Cancer Center
who collaborated on the Vineti software. “Mayo Clinic
is a Center of Excellence in delivering CAR-T therapy. Our team is acutely
aware of the impact of innovative software on improving patient care.  We are happy to share our expertise with
Vineti to enable the optimization of their software that brings together different
groups to ensure safe and timely delivery of cells to the right patient.”

Allan Dietz, Ph.D.

Mayo Clinic Cancer Center and the Department
of Laboratory Medicine and Pathology
 Immune, Progenitor, and Cell Therapeutics Lab
(IMPACT) collaborated on the software.  Mayo Clinic Center for Regenerative Medicine provided
support. The research for this software was done within the IMPACT laboratory,
Therapeutic Apheresis Treatment Unit (TATU) and the division of Hematology, as
part of the effort to improve cell therapies for patients. Key innovators are Allan
, Ph.D., Dr.Lin, and Jeffrey
Winters, M.D.

“This award demonstrates the importance and transformative
nature of cell-based therapies for our patients. It is also a great example of
leadership role of innovation and application that the IMPACT lab and
transfusion medicine is having at Mayo and around the world,” says Dr. Dietz.

Jeffrey Winters, M.D.

“CAR T therapy is a rapidly growing treatment which is
critical for the treatment of a variety of patients who have no other options. The
Vineti software ensures that appropriate quality controls are in place for the
therapies to ensure patient safety. The award recognizes their critical role in
this area,” says Dr. Winters.

The software is also used to track cell processing for a
range of other conditions, including rare genetic blood disorders. Cell therapy
is being pursued in a wide range of serious disorders, including cardiac and
inflammatory conditions.

Vineti began as a collaboration between Mayo Clinic and GE
Ventures. Mayo Clinic has retained an ownership stake in the company. Any
revenue generated is reinvested in Mayo Clinic research and education.

Wed, May 29 6:00am · Sudden Cardiac Death: Defining the Risk for Surviving Relatives

Article by Barbara Toman

A young person’s sudden death from cardiac arrest is doubly devastating. Just when family members are mourning the unexpected loss, they might also be wondering if tArhe cause was inherited heart disease — and if they too are at risk.

there’s no easy answer. Unlike certain cancers with strong links to a single
gene abnormality, cardiovascular disease is associated with complex genetic
factors. Blood relatives of people who experienced sudden cardiac death can
face a lifetime of uncertainty and annual medical imaging to detect any signs
of heart disease.

With support from the Center for Individualized Medicine, Mayo Clinic is conducting research to find answers.

Maleszewski, M.D.

“Surviving family members don’t know if they are at risk for a heart condition, if they should change their lifestyle such as not engaging in certain types of athletics— they’re just stuck,” says Joseph Maleszewski, M.D., a Mayo Clinic pathologist specializing in cardiovascular disease. “We’re trying to elucidate the underlying genetic implications for these family members. We want to help them manage diagnostic screening and get the care they need right now.”

unexpected death from cardiac arrest accounts for 12% to 15% of natural deaths.
Up to half of people under age 35 who experience sudden cardiac death had no
family history of it and no warning signs of heart disease, according to the
National Society of Genetic Counselors.

in partnership with the Windland Smith Rice Sudden Death Genomics Laboratory
& Long QT Syndrome Clinic, Mayo Clinic’s research involves postmortem
analysis of the hearts from people under age 40 who died suddenly of presumed
cardiac causes, and genetic testing of first-degree relatives—parents, siblings
and children. “We believe it’s absolutely necessary to combine these two
approaches in order to give the family information that’s much more useful than
what they would get from either approach alone,” Dr. Maleszewski says.

Subtle signs that lead to answers

common challenge for family members is incomplete information about the cause
of a relative’s sudden death. An autopsy might establish that the person died
of natural causes but fail to identify a specific cardiac disease or its
genetic underpinning.

believe some cases of sudden cardiac death are very subtle manifestations of
cardiomyopathy, or heart muscle disease. The features of cardiomyopathies are
sometimes very difficult to detect, even by experienced medical examiners and
coroners,” Dr. Maleszewski says.

postmortem examinations conducted by Mayo Clinic cardiovascular pathologists will
evaluate each heart’s overall appearance and analyze tissue sections under the
microscope. If cardiomyopathy is suspected, genetic testing will be recommended
for first-degree relatives.

who test negative for genetic variants associated with heart disease can avoid
routine imaging. For family members who do have a genetic variant, risk-management
plans can be developed.

think this is a much more scientific and comprehensive approach to cases of
sudden death,” Dr. Maleszewski says. “Instead of a 20th-century
screening paradigm, we want a 21st-century pairing of postmortem examination and
genetic testing.”

That pairing
is key. “There’s a lot of nuance in the understanding of cardiovascular disease.
Our interpretation of the genetic tests is completely contingent on
establishing with our eyes that there is some type of underlying pathology in
the heart,” Dr. Maleszewski says. “We can then give information to
the family that empowers them to obtain efficient screening and to have
complete closure.”

common challenge is a lack of genetic information about the deceased relative.
Postmortem blood samples are stored for a limited time — due to cost and space
constraints experienced by medical examiners — and so often aren’t available
for genetic testing.

Clinic has developed a unique genetic test that uses tissue samples preserved
in paraffin. Unlike blood samples, those tissue samples are often kept by
medical examiners for several years to meet accreditation requirements.

use this tissue-based genetic testing routinely. It opens up a lot of older
cases for possible interrogation,” Dr. Maleszewski says. “For
example, if a Mayo cardiologist sees a patient whose father had cardiac death
at a young age, we can obtain the father’s tissue samples, examine them and
then determine if genetic testing should be done to assess the son’s risk.”

accumulated will also provide insight into the complex genetic variations that
can cause heart disease.

we hope that for every case of sudden cardiac death, there can be a complete
workup of the heart and the genetics,” Dr. Maleszewski says. “We’d
like to help educate medical examiners and coroners on how to perform a thorough
cardiovascular exam to look for these subtle signs of disease, and to give them
access to expert consultation when they need it.”

Clinic’s study is being conducted through medical examiners and coroners who
refer new cases of sudden death in which a cardiac cause is strongly suspected.



to read more stories like this one?

Register to get weekly updates about new
stories on Mayo Clinic Center for Individualized Medicine blog.

the date!

from and network with researchers and innovators in oncology at

Medicine 2019 Conference: Precision Cancer Care through Immunotherapy and

Tue, May 7 6:00am · Rare, undiagnosed diseases are relatively common

As many as 25 million Americans – about 1 in 13 people – suffer from a rare, undiagnosed condition.* April 29 was designated Undiagnosed Disease Day to raise awareness that collectively, rare diseases are relatively common. People with a rare disease often spend years visiting different medical providers and clinics seeking answers to unexplained conditions. Mayo Clinic Center for Individualized Medicine brings together a team of experts, the most sophisticated genomic testing and worldwide research to solve complex, undiagnosed cases,

Genetic sleuthing of puzzling cases

The Human Genome Project the
first mapping of a person’s genetic blueprint has
unlocked mysteries of rare diseases that for ages bewildered medical science. Completed
just 16 years ago, the Human Genome Project has ushered in a new era of
individualized medicine that has significantly advanced the ability to diagnose
rare, genetic diseases.

The Center for Individualized Medicine’s experts,
who make up the Genomic Odyssey Board, consult clinical findings, DNA testing and
research to solve rare disorders. Patients come from around the world seeking a
diagnosis. DNA testing offers a genetic trail of clues that sometimes leads
researchers and clinicians to a scientific pot of gold: a diagnosis that no one
else has been able to make. Even if there’s not a treatment, having a diagnosis
can be life changing. Patients can stop spending time and money visiting
countless health care providers in search of answers.

Mayo Clinic has been able to diagnose
approximately 30 percent of patients with unexplained genetic disorders. The
Genomic Odyssey Board would like to close the gap on the other 70 percent of
cases that go unsolved, and advancements in tools offer hope for a better
success rate.

Dr. Heidi Rehm:  Data sharing brings new answers for everyone

The promise of DNA sequencing also brings the
challenge of interpreting big data. Consider this: sequencing one patient’s
genome generates data so massive that if stacked end-to-end, it would reach
from earth to the moon. Finding disease-related genetic variants within those
results can be like looking for a needle in a haystack.

Heidi Rehm, Ph.D., a geneticist and genomic medicine researcher at the Broad Institute Chief Genomics Officer at Massachusetts’s General Hospital and Professor of Pathology and Harvard Medical School, has called for broader knowledge sharing of disease-related variants in order to zero in on disease-causing genes.

Dr. Rehm, who presented at the 2018
Individualizing Medicine Conference, says databases where researchers and
clinicians share information about genetic variants, interpretations and
evidence linking genes to specific health care disorders, have greatly advanced
understanding of rare, genetic diseases.

Heidi Rehm, Ph.D.

“It’s a
combination of crowd sourcing the challenge, sharing the evidence, identifying
when we might view evidence differently, and validating the findings,” says Dr.
Rehm. “If we’re really going to
integrate genetics into the practice of medicine, we need to ensure that the
information we are returning to patients is valuable and accurate. We need
resource sharing across the community to do that.”

Dr. Rehm identified three key genomic data
sharing sites that are improving the chances of finding a diagnosis:

  • ClinVar
    a variant database where laboratories and research groups share interpretations
    of rare disease-related variants.
  • ClinGen
    a large NIH program that develops standards and assembles
    experts to compile and review evidence and for assessing the role of genes and
    variants in disease.
  • Matchmaker
    – a platform for building evidence for genes
    implicated, but not proven to be linked to disease.

from data sharing sites helped establish best practices in genetic and genomic
testing, leading to more reliable and consistent results.

“This means patients are more likely to have
their disease-causing variants identified as causal rather than classified as a
variant of uncertain significance. As a result, they are more likely to get an
accurate and consistent diagnosis that stands up to testing from multiple
labs,” says Dr. Rehm.

Dr. Eric Klee: New tools and new technology on the horizon

Mayo Clinic is developing computer software
that would analyze genetic data from unsolved cases in which the trail has gone
cold. The software program would send alerts when new research reveals
understanding of a gene that could crack a case.

Eric Klee, Ph.D., associate director of the Mayo Clinic Center for Individualized Medicine Bioinformatics Program, envisions a tool that would constantly update former variants of unknown significance, going back to the very first unsolved cases analyzed five or six years ago.

Eric Klee, Ph.D.
Eric Klee, Ph.D.

“We are in a unique time frame in the history of mankind in that we are learning exponentially more all the time about genetic disease. What we know today is so drastically different from what we knew even a year ago,” says Dr. Klee. “Tools that allow us to automatically go back and analyze cases in terms of new knowledge are going to be very important.” 

Dr. Klee, who also presented  at the 2018 Individualizing Medicine
Conference, envisions new tools that would broaden data sharing to include both
genotype (genetics) and phenotype (visible characteristics such height, eye
color, overall health status and disease history) in a centralized, worldwide database.

“That unleashes the power of experts from
around the world to solve rare cases rather than just from one institution,”
says Dr. Klee. “The ability to learn and diagnose would be significantly

On the technology side, Dr. Klee predicts whole
genome sequencing
which covers all a person’s DNA will
replace the current practice of sequencing only the known disease causing
genes. That will give investigators additional information on how changes
within the genetic blueprint might be causing disease. He believes RNA
sequencing, which reveals defects within the genes, will also be increasingly
used. That may improve the solve rate for patients who are seeking a diagnosis
after suffering for years from an unknown disease.

*National Institutes of Health

This article originally was published on the Center for Individualized Medicine blog on April 16, 2019.

Join the conversation

For more information on the Mayo Clinic Center
for Individualized Medicine
, visit our blogFacebookLinkedIn or Twitter at @MayoClinicCIM.

Tue, Apr 23 6:00am · Testing the bugs within to maintain health, detect and treat disease

Article by Sharon Rosen

Purna Kashyap, M.B.B.S.

The use of microbiome testing – which analyzes the trillions of bacteria in and on the body – is on the move. It’s going from the research lab into the clinic to help guide patient care. DNA testing technologies have revolutionized researchers’ ability to identify individual bacterial strains driving disease. Now genomic testing is helping diagnose the source of infections, develop personalized diets, find new treatments for functional and inflammatory conditions of the gut and identify new screening tools for certain cancers.

For Purna Kashyap, M.B.B.S., this is just the beginning. As the Bernard and Edith Waterman co-director for the Mayo Clinic Center for Individualized Medicine Microbiome Program, Dr. Kashyap envisions the coming years as a pivotal time for moving the latest discoveries from the lab to new diagnostic tests and individualized microbiome-based therapies for patients.

“Just as genomics plays a key role in personalized medicine, the microbiome also affects our individual health – boosting our immune system, helping us digest food and influencing how we respond to medications. We are each born and live with a unique microbiome. But unlike our genes, the microbiome can be manipulated and changed. That’s why physicians need to consider the role of the microbiome, along with genetics and other factors, especially when treating patients with complex diseases like autoimmune disorders, gastrointestinal diseases, diabetes, obesity and many types of cancer,” says Dr. Kashyap.

Technologies developed in the lab provide answers in the clinic

A high fever, increased blood pressure and rapid heart rate – these are all symptoms that could be caused by an infection. But for some patients, traditional blood tests fail to identify the source of the illness. That’s where microbiome testing technologies developed in the laboratory are already helping to find answers for Mayo Clinic patients. Within a day and in some cases just hours, the testing is revealing the source of a previously undiagnosed infection, allowing for treatment with targeted therapies.

“We can now identify the specific bacteria causing serious infections even though we are not able to culture them” says Dr. Kashyap.

Test results can help physicians choose targeted therapies to treat infections and avoid the use of “dynamite” antibiotics explains Dr. Kashyap.

“Genomic testing allows us to select specific therapies to kill only the bacteria causing the infection, rather than prescribing an antibiotic that eliminates all of the gut bacteria, leaving the patient susceptible to other illnesses,” says Dr. Kashyap.

Next steps – identifying biomarkers to predict, diagnose and treat disease

To expand the use of microbiome testing, Dr. Kashyap and his colleagues are collaborating with the Center’s Clinomics Program to integrate microbiome testing into patient care as well as clinical trials. Their goal is to identify microbiome biomarkers that could be used to develop screening tests to detect early signs of disease or new individualized therapies, tailored to a person’s microbiome.

Going forward, microbiome testing may also provide important information about disease risk for healthy patients.

“This testing could provide healthy patients with information about disease risk and help define steps they can take to manage their health,” says Dr. Kashyap.

Eat this, not that – personalized diets

Dr. Kashyap and his colleagues have recently tested a model that successfully predicted changes in blood glucose (sugar) levels based on an individual’s age, lifestyle habits and microbiome.

“With the model, we can manage blood sugar levels by changing diet to match the microbiome rather than trying to change the microbiome which may take time”” says Dr. Kashyap.

Dr. Kashyap and his team have also uncovered a link between a person’s microbiome and their ability to lose weight.

“In a pilot study, we found that after switching to a lower-calorie-diet rich in fruit and vegetables, some people were able to lose weight more easily than others due to the type of bacteria in their gut.”

Learn more about the team’s research here.

Matching research to patient needs – a focus on gut health

Throughout his career as a gastroenterologist, Dr. Kashyap has focused on conducting research to meet the needs of his patients.

He has explored how gut bacteria control normal gut function and contribute to the development of gastrointestinal disorders, such as irritable bowel syndrome.

In addition, he has investigated how bacteria lead to opportunistic infections that can become life threatening, such as c. difficile, which can occur after a patient has had a prolonged stay in a hospital or nursing facility. The Mayo team has used new treatment approaches, including fecal transplants, to restore these patients’ gut microbiome with healthy bacteria.

“Some patients have a microbiome composition that makes them more susceptible to c. difficile infection. We are working on strategies to prevent the infection as well as develop a treatment with a bacteria-containing pill.”

For Dr. Kashyap, these research efforts are just the tip of the iceberg. “As we learn more, we’ll be able to offer patients better screening and treatment for a wide range of diseases, tailored to their unique needs.”

Pushing the envelope to uncover causes, new treatments for colorectal cancer

Read the related article, highlighting Microbiome Program co-director Nicholas Chia, Ph.D., and his research to uncover early signs of colorectal cancer to improve screening and treatment for the disease.


This article originally appeared on the Individualized Medicine blog on April 2, 2019

Stay informed

Want to read more stories like this one?

Register to get weekly updates about new stories on Mayo Clinic Center for Individualized Medicine blog.

Join the conversation

For more information on the Mayo Clinic Center for Individualized Medicine, visit our blogFacebookLinkedIn or Twitter at @MayoClinicCIM.

SAVOR, SUBSCRIBE, SHARE:  Advancing the Science

  • If you enjoyed this article, you might want to subscribe for regular updates.
  • If you want to share this story with friends, social media links are at the top of the article.
  • And if you want to see other recent stories on the blog, the index page is a great place to start.

Wed, Apr 10 6:00am · Genetic testing reveals risk, steps to prevent aortic dissection

Article by Sharon Rosen

Stephanie Van Doren and her family

Stephanie Van Doren never realized that taking 30 mile bike rides in the Florida heat was putting her life at risk. But, care for digestive problems also uncovered that she was at risk for an aortic dissection, a potentially fatal condition that could occur with intense exercise. Her care team at Mayo Clinic’s campus in Florida quickly connected the dots. Her family history and physical exam painted a picture that pointed to a hereditary condition. They recommended genetic testing and the results provided lifesaving information to Van Doren and her family.

Unraveling a medical mystery through genetic testing

Sarah Macklin

Van Doren met with Sarah Macklin, a genetic counselor in the Department of Clinical Genomics and Center for Individualized Medicine.

During the first appointment, Macklin mapped Van Doren’s family medical history for three generations. They also discussed the benefits, risks, and limitations of testing, and what steps could be taken if any of the tests came back positive.

Van Doren had testing to explore two questions: did she have any identifiable genetic risk factors that significantly increased her risk of having a thoracic aortic aneurysm and aortic dissection? Did she have any identifiable genetic risk factors that significantly increased her risk for breast cancer since her sister had died from the disease at a young age?

Results showed that she did have the genetic risk factor for aortic dissection, but did not have a genetic risk identified for breast cancer.

“I was devastated that I was at increased risk for aortic dissection. This runs deep in my family and I had seen firsthand how it has affected my relatives,” she says.

Many members of Van Doren’s family had an aortic dissection at a young age. The condition can be life threatening and occurs when the inner layers of the aorta, the large blood vessel branching off the heart, tear.

As a result, she and her family decided that her children should also have genetic testing. They met with Macklin to learn more about the process and implications.

“This second conversation is much different than the first,” explains Macklin. “We now are looking for a particular genetic variant that has been identified in a parent or other family member. We take time to explain to children – in terms that they can understand – what we are looking for, why we are looking for it and what it will mean if the test comes back positive.”

“It’s very important to be honest with children so they can understand and agree to have the testing, even if they are not old enough to give the consent themselves.”

Two of Van Doren’s three children have the gene variant linked to aortic dissection. She received these results first and then shared them with her children.

“It was important for me to have time to process the results myself and then explain them to my children,” she says.

Macklin also shared the genetic test results with Mayo specialists in Cardiovascular Medicine who are providing Van Doren e and her children with the monitoring and follow up care they need to stay healthy.

“Never did I imagine that I would have genetic testing, but thankfully I did – the results probably saved my life and will help my children live a healthier life.” she says. “It’s difficult to learn that you are at risk for such a serious condition. But now we have the information we need to be proactive and stay healthy.”

Know and share your family medical history with your health care team 

Timothy Woodward, M.D.

Van Doren first came to Mayo seeking relief from digestive problems. It was her gastroenterologist, Timothy Woodward, M.D., who first recognized that her family history plus characteristics he observed during her physical exam pointed to the possibility that she had a hereditary condition.

“Ms. Van Doren did what we hope all patients will do – know and share their family medical history with their physicians,” says Dr. Woodward. “This information plus a complete clinical evaluation allows us to provide patients with individualized care, tailored to their needs.”

Moving forward – living life to the fullest

“I have always led a very active lifestyle – enjoying skydiving and leading group fitness classes. Now I am unable to do these things. I can exercise, but I need to pay close attention to my heart rate and avoid intense exertion. My children can still do many of the activities they love and will continue to be monitored as they grow,” Van Doren explains.

Looking back, she reflects that there were definitely highs and lows during the genetic testing process. Thanks to the coordinated efforts of her Mayo Clinic care team, she and her family found the answers they needed.

“We have moved on – each day is filled with activities for 3 busy children – we’re living life to the fullest.”


This article originally appeared on the Individualized Medicine blog on March 26, 2019

Stay informed

Want to read more stories like this one?

Register to get weekly updates about new stories on Mayo Clinic Center for Individualized Medicine blog.

Save the date!

Learn from and network with researchers and innovators in oncology at

Individualizing Medicine 2019 Conference: Precision Cancer Care through Immunotherapy and Genomics

Key themes include:

  • CAR-T therapy
  • Clonality
  • Pharmacogenomics
  • Lineage Plasticity
  • National Cancer Institute.

Join the conversation

For more information on the Mayo Clinic Center for Individualized Medicine, visit our FacebookLinkedIn or Twitter at @MayoClinicCIM.



SAVOR, SUBSCRIBE, SHARE:  Advancing the Science

  • If you enjoyed this article, you might want to subscribe for regular updates.
  • If you want to share this story with friends, social media links are at the top of the article.
  • And if you want to see other recent stories on the blog, the index page is a great place to start.

Thu, Mar 21 6:00am · Colon cancer: a new era in cancer screening and detection

Image of DNA with "family" written in itMarch is Colorectal Cancer Awareness Month, a time to focus on one of the most common and preventable forms of cancer. Mayo Clinic is applying a new genomic lens to colorectal and other cancers to identify which are the types that run in families. The answer to that could open new treatment options and also take the guess work out of who else in your family is at higher risk for cancer.

Niloy “Jewel” Samadder, M.D., a gastroenterologist at Mayo Clinic’s Arizona campus, is leading efforts to usher in a new era of screening and detection that focuses on identifying hereditary cancers. Research shows that 1 in every 15 cases of colon cancer and possibly up to 1 in every 5 cases of cancer overall are linked to underlying inherited genetic mutations.

A diagnosis of hereditary cancer often changes treatment to an individualized approach shaped by a patient’s genetic makeup. Mayo Clinic, with the support of the Center for Individualized Medicine, is moving toward testing all cancer patients for such inherited mutations — not just patients with cancer in their family tree.

photo of Dr. Niloy "Jewel Samadder

Niloy “Jewel” Samadder

“If we know that cancer was genetically predisposed, it can lead to unique options ensuring that treatments target the cancer and minimize side effects,” says Dr. Samadder. “For example, research shows that certain targeted chemotherapies and immunotherapies are not specific to the type of tumor or cancer but really act on certain molecular pathways. So, whether that cancer is colon, prostate or breast, we can respond with a drug that is targeted to the genetic mutations that caused that cancer rather than a specific tumor.”

To identify hereditary cancer, Mayo uses a robust DNA blood test panel that examines genes known to have links to cancer.

“This is the most comprehensive cancer genetic panel available today,” says Dr. Samadder. “We believe this gives us the tools for catching and treating inherited cancers that might have gone undetected in the past.”

If this test finds you have an inherited cancer, there is a 50 percent chance your immediate family members have the same genetic alteration that would increase their chance of developing a similar cancer. Under current cancer screening guidelines, up to half of all inherited cancers go undetected — a missed opportunity for early detection and possibly even cancer prevention.

Those with a genetic predisposition face a greater than average lifetime risk for cancer, but it is not 100 percent certain they would develop the disease. Lifestyle and environment also play a role in cancer risk.

Prevent a second cancer

Keila Alvarado of Phoenix was diagnosed with rectal cancer in 2008 at the age of 32. Genetic testing revealed Lynch syndrome, a hereditary condition that puts her at higher risk of developing colon, ovarian, uterine, stomach and other cancers.

Photo of Keila Alvarado

Keila Alvarado

“I was surprised. I really didn’t understand much about genetics at the time. I’m happy to have this information, because it’s better to be prepared. I now understand my risk for future cancers,” says Alvarado.

With grit and determination, Ms. Alvarado fought rectal cancer with surgery, chemotherapy and radiation. Now in remission, she has turned her attention to a new challenge: preventing a second type of cancer related to Lynch syndrome. She’s had a pre-emptive hysterectomy, has yearly blood work and screenings and is vigilant about her health.

“Any time the doctor says this is a preventive measure, I’m like, ‘ya, let’s do it.’ I don’t mind the different tests. I also take seriously my intake of food and how I can eat healthier. I try to be conscious of what I do and live a healthy lifestyle,” she says.

Now others in Alvarado’s family know they, too, could be at risk of inherited mutations that put them at higher risk for cancer. Some family members have chosen to have genetic testing, and those who also tested positive for Lynch syndrome can take a proactive approach to prevention.

“For patients with Lynch Syndrome, we suggest earlier and more frequent screenings. We recommend the first colonoscopy at age 20 and then once every one to two years after that. That’s different from the normal population where we start at age 50 and test every five to 10 years after that. We also recommend more frequent imaging, blood work, urine tests and skin exams,” Dr. Samadder says. “We would also refer females to a gynecologist to monitor for risks of uterine and ovarian cancer — possibly even recommending pre-emptive surgery.”

In some cases, Mayo will refer patients for chromoendoscopy, an ultra-sensitive screening which applies a special stain during a colonoscopy to detect polyps that might have otherwise been missed.

Dr. Samadder says Keila Alvarado’s case is a great example of how a new era of genetic screening can help inform family members who might not have known they are at higher risk of cancer. They can respond proactively to try to prevent cancer or catch it an early stage when it is curable.


This article was taken from the March 12, 2019 post on the Individualized Medicine blog.

Stay informed

Want to read more stories like this one? Register to get weekly updates about new stories on Mayo Clinic Center for Individualized Medicine blog.

Save the date!

Learn from and network with researchers and innovators in oncology at

Individualizing Medicine 2019 Conference: Precision Cancer Care through Immunotherapy and Genomics

Westin Kierland Resort & Spa
Scottsdale, Arizona
Sept. 20-21, 2019

Join the conversation

For more information on the Mayo Clinic Center for Individualized Medicine, visit our FacebookLinkedIn or Twitter at @MayoClinicCIM.


SAVOR, SUBSCRIBE, SHARE:  Advancing the Science

  • If you enjoyed this article, you might want to subscribe for regular updates.
  • If you want to share this story with friends, social media links are at the top of the article.
  • And if you want to see other recent stories on the blog, the index page is a great place to start.

Wed, Mar 13 6:00am · Business innovation with an eye on improving vision

Destination Medical Center – One Discovery Square

If eyes are the window to the world, Timothy W. Olsen, M.D. is building high performance window frames. With a passion for restoring vision, the ophthalmologist set sights on developing and bringing to market a first-of-its-kind device for treating age-related macular degeneration. The synergies around the Destination Medical Center economic initiative and Mayo Clinic’s research and practice community prompted him to move his business and clinical/surgical practice from Atlanta to Rochester, Minnesota.

Timothy W. Olsen, M.D.

“The business environment is second to none. Mayo has made a statement through Destination Medical Center that it wants to be an innovation center for medical technology,” says Dr. Olsen. “That combination of business, technology and connection to Medical Alley bio businesses in Minnesota makes this is a really good place to develop and commercialize medical devices.”

Destination Medical Center is a 20-year, multibillion dollar public-private partnership to position Rochester as a global destination for health care, biotechnology and life science discoveries. The money supports public infrastructure and does not go to Mayo Clinic. The convergence of entrepreneurship, medical expertise and regulatory support, Dr. Olsen says, is the perfect place for a successful product launch.

“Destination Medical Center is the city of Rochester, Olmsted County and the state of Minnesota. With those components, hopefully there will be private sector support as well as the opportunity for engaging with people involved in funding early stage start-up companies, including venture capital funding opportunities,” says Dr. Olsen.

A new device for age-related macular degeneration

Macular degeneration affects more than 3 million Americans and is the leading cause of vision loss for people over 50. There is no cure or treatment in the early stages. Patients with end stage macular degeneration may be suitable for monthly eye injections, but that is expensive and inconvenient. The disease process usually progresses despite the injections.

That’s where Dr. Olsen’s business comes in. His team is advancing research on a surgically-implantable device, using a technology that was first conceived at the University of Minnesota and patented through Emory University. That device acts as a window or picture frame holding regenerative tissue in place to support the macula at the back of the eye, potentially reversing vision loss and preserving the function of the macula.

The National Institutes of Health/National Eye Institute awarded a Small Business Technology Transfer Research grant for a one-year, phase I feasibility study. The grant goes directly to Dr. Olsen’s company, located in the Mayo Clinic Business Accelerator, with sub grant funding for preclinical research at Mayo.

“The goal of this research grant is to support scientists launching commercialization of a product rather than the researcher studying technology from an outside company, in an effort to speed the movement of a product from the research lab into the marketplace,” says Dr. Olsen.

After the feasibility study, there is a possibility of additional early-stage funding through a larger two-year, phase II National Institutes of Health research grant. Once that is completed, access to private capital would likely be needed to continue product development. Dr. Olsen believes the entrepreneurial environment created through the Destination Medical Center initiative will help attract that private investment. If the device passes regulatory approvals, it may take five to 10 years before it is offered in a clinical setting to address the unmet needs of millions of people suffering from age-related macular degeneration.


SAVOR, SUBSCRIBE, SHARE:  Advancing the Science

  • If you enjoyed this article, you might want to subscribe for regular updates.
  • If you want to share this story with friends, social media links are at the top of the article.
  • And if you want to see other recent stories on the blog, the index page is a great place to start.

Thu, Mar 7 6:00am · What do Yellowstone rocks teach us about kidney stones

This article originally appeared on the Center for Individualized Medicine blog.

Mayo Clinic researchers are turning to Yellowstone National Park to unlock the secrets of kidney stones. Medical science long has been mystified by a cause and cure for this painful condition that affects more than 1 in 10 Americans. Mayo Clinic Center for Individualized Medicine and NASA Astrobiology Institute research finds kidney stones grow in dynamic ways that are similar to those observed in Mammoth Hot Springs rock formations at Yellowstone.

Nicholas Chia, Ph.D.

“For decades, we thought that kidney stones formed in a slow, steady, layer-by-layer process like dust settling in your house. However, new high-resolution cross sections of these stones indicate they repeatedly grow and dissolve on their way to becoming a fully formed stone. There are periods of rapid growth, large missing gaps and dissolution — it’s a back-and-forth process. This suggests that stones grow over time in a more complicated way than we previously knew, and that there may be new ways to prevent them,” says Nicholas Chia, Ph.D., co-director of the Mayo Clinic Center for Individualized Medicine Microbiome program. “We are very excited because we see the same types of patterns in kidney stones, Yellowstone rocks and many other environments on Earth.”

The kidney stone studies bring together geobiologists, microbiologists and nephrologists to prove their theory. The smoking gun, Dr. Chia says, would be a discovery that microbes — common bacteria — are driving kidney stone formation in the same way they do in Yellowstone hot spring deposits.

Kidney stone cross section

“We believe stone formation is microbially driven in the human body as well. We are trying to extract and genetically sequence the microbes and proteins that are present to figure out where they are in the stone and what processes they are responsible for,” says Dr. Chia. “We hope to answer this in future studies.”

Kidney stones are hard rocklike masses of mineral and acid salts often smaller than the head of a nail that lodge in the kidney and don’t dissolve. The only way to get rid of them is through painful urine passage or surgery.

The team is now working to understand how proteins and other biomolecules derived from both the kidney and the microbiome — the community of bacteria in your body — could lead to an eventual treatment. That’s especially important for people who follow medical advice and yet repeatedly suffer from kidney stones.

Yellowstone cross section

“If we understood the process of repeated crystallization and dissolution within kidney stones, we might be able to prescribe something that either dramatically slows the stone growth or significantly increases the disintegration. If we understood the diversity of microbes involved and their metabolic activity, we might be able to change the rates at which stones growth and dissolve, just as has been proven by research in Yellowstone hot springs. There are many options once we understand this process,” adds Dr. Chia.

Dr. Chia’s team has been working on these studies for approximately five years. He believes it will take a few more years of team science research to fully understand the combined role of the microbiome, renal (kidney) physiology and urine chemistry in growing and dissolving kidney stones.

Up to a half-million people a year visit the emergency room to seek relief from this condition, according to The National Kidney Foundation. Kidney stones are often associated with other disorders such as high blood pressure, diabetes and obesity.

Dr. Chia is the Bernard and Edith Waterman co-director of the Mayo Clinic Center for Individualized Medicine Microbiome Program.

Join the conversation

For more information on the Mayo Clinic Center for Individualized Medicine, visit our blogFacebookLinkedIn or Twitter at @MayoClinicCIM


Read related content from Advancing the Science.


SAVOR, SUBSCRIBE, SHARE:  Advancing the Science

  • If you enjoyed this article, you might want to subscribe for regular updates.
  • If you want to share this story with friends, social media links are at the top of the article.
  • And if you want to see other recent stories on the blog, the index page is a great place to start.
Contact Us · Privacy Policy